Incyte Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INCY research report →
Companywww.incyte.com
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic.
- CEO
- William J. Meury
- IPO
- 1993
- Employees
- 2,617
- HQ
- Wilmington, DE, US
Price Chart
Valuation
- Market Cap
- $19.37B
- P/E
- 13.50
- P/S
- 3.61
- P/B
- 3.48
- EV/EBITDA
- 8.53
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 91.86%
- Op Margin
- 26.85%
- Net Margin
- 26.71%
- ROE
- 29.31%
- ROIC
- 19.98%
Growth & Income
- Revenue
- $5.14B · 21.22%
- Net Income
- $1.29B · 3844.96%
- EPS
- $6.59 · 4018.75%
- Op Income
- $1.34B
- FCF YoY
- 443.87%
Performance & Tape
- 52W High
- $112.29
- 52W Low
- $63.51
- 50D MA
- $95.35
- 200D MA
- $95.06
- Beta
- 0.80
- Avg Volume
- 1.52M
Get TickerSpark's AI analysis on INCY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 8, 26 | BAKER BROS. ADVISORS LP | other | 15,000 |
| May 8, 26 | BAKER BROS. ADVISORS LP | other | 15,000 |
| May 8, 26 | BAKER BROS. ADVISORS LP | other | 15,000 |
| May 4, 26 | Upadhyay Suketu | other | 38,429 |
| May 4, 26 | Upadhyay Suketu | other | 26,343 |
| May 4, 26 | Upadhyay Suketu | other | 13,171 |
| May 4, 26 | Upadhyay Suketu | other | 0 |
| Apr 17, 26 | CAGNONI PABLO J | other | 12,590 |
| Apr 17, 26 | CAGNONI PABLO J | other | 6,077 |
| Apr 17, 26 | CAGNONI PABLO J | sell | 18,667 |
Our INCY Coverage
We haven't published any research on INCY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate INCY Report →